In the next 10 years, China's three major focuses in the field of biomedicine deserve attention

[pharmaceutical network industry trends] at present, under the background of continuous promotion of medical reform policies and changes in the industry pattern, many pharmaceutical people are very concerned about whether the golden pattern of the pharmaceutical industry will continue in the next 10 years? What will be the development trend if it continues? It happened that on December 28, at a pharmaceutical forum, some experts in the industry predicted some focus in the field of biomedicine in the next decade After combing and summarizing, I'd like to share with you Innovation will run through many aspects of the biomedical industry With the continuous breakthrough of biomedical technology, China's biomedical industry is developing rapidly In recent years, the scale of China's biomedical industry continues to grow, and the proportion of biomedical output value in the pharmaceutical industry continues to rise In 2018, the revenue of several top listed companies in biomedical related fields, such as McAb, blood products, vaccines and so on, exceeded 100 million yuan, achieving year-on-year growth and good industry development trend On the whole, the trend of more openness to promote the development of pharmaceutical globalization in the future is unstoppable Capital technology market will promote restructuring and M & A, and smart manufacturing will also have breakthroughs The new drug law and Chinese pharmaceutical demand or the promotion and acceleration of original new drugs will give priority to the application review and listing in China In addition, with the increase of the number of Listed Companies in China's biomedical industry, the competition between the industry and enterprises will be more intense At the same time, the development of generics will also be impacted At present, the consistency evaluation, the "4 + 7" centralized purchase and other policies are profoundly changing the generics industry, and the traditional value of the first generics and bio generics is rapidly fading As a result, at present, in addition to the advantages of its main varieties, some pharmaceutical leading enterprises with strong R & D strength have distributed incremental varieties one after another, and a large number of generic varieties have rapidly become the Red Sea; coupled with the time advantage of the first generic is being wiped out, domestic generic pharmaceutical enterprises will gradually return to the source of value of the manufacturing industry
In the future, the main market of China's generic pharmaceutical enterprises will include both domestic and overseas markets, because there is no doubt that Chinese enterprises have unique advantages in the integrated development of industrial chain, production cost and efficiency that other countries do not have, and they are very likely to become the global leader in the generic pharmaceutical industry in the future; and in the development mode, "big and all" and "small and beautiful" will be China There are two directions for the development of generic pharmaceutical enterprises, especially because China has developed a large number of cro and cdmo enterprises because of its cost advantage The development mode of "small but beautiful" in the subdivision field is worth looking forward to At the same time, the industry insiders also pointed out that the status of generic drugs will not change in the next 10 years, the prospect of cooperation and development of foreign enterprises is promising, and the pace of domestic generic drugs to the world will be accelerated; while the foreign generic drugs or enter with their cost and quality advantages, or will threaten the development of China's generic drugs Chinese medicine will usher in the opportunity period under the favorable policies Chinese medicine is the wisdom crystallization of China's five thousand year civilization, which has continuously promoted the development of China's medical and health undertakings The state has always attached great importance to the inheritance and development of traditional Chinese medicine technology and culture It has not only proposed to revitalize the cause of traditional Chinese medicine, but also made various strategic arrangements Thanks to this, in the past few years, the market scale of Chinese medicine health industry has continued to rise, maintaining a double-digit high-speed growth In 2017, it has reached 1750 billion yuan, up 21.1% year on year According to China's traditional Chinese medicine, by 2020, China's great health industry of traditional Chinese medicine will exceed 3 trillion yuan, with an annual compound growth rate of about 20% In the future, with a series of favorable policies, evidence-based medicine research on the quality and clinical efficacy of traditional Chinese medicine resources may have a breakthrough development; the development of classic famous prescriptions may lead to a revolution in research and development of Chinese patent medicine; and the development prospect of medical care combined with domestic and international needs will be promising.